Type 1 diabetes is still treated with insulin injections. Insulin is supplied in a variety of long, intermediate and short-acting preparations. The duration of action of insulin preparations required to give optimal control varies from patient to patient. This means that individual patients are established on particular regimens which are not changed unless they are [...]
(See PRLog press release at link.) As well established as the practices are for the management of types 1 and 2 diabetes, a raft of new technologies, from modest to radical, are steadily entering clinical practice and the industry, according to a new report from MedMarket Diligence. FOR IMMEDIATE RELEASE PRLog (Press Release) – Aug [...]
The applications of surgical sealants, glues and wound closure are many and are rapidly multiplying as more credible data is generated on each application and as physicians gain comfort in working with the products in routine clinical practice. Below is a sample of surgical sealants, glues and wound closure applications by clinical area: Source: [...]
Cancer is a significant opportunity for the development of tissue engineering and cell therapies, but it is more than just an opportunity currently, since many companies are active and the market for cancer cell/tissue therapies already stands at nearly $500 million. Currently, OSI Pharmaceuticals has a commanding lead in this area, with its Tarceva [...]
The global market for coronary stents is estimated to be in excess of $7 billion and projected to be growing at 6% per year. With the average age of citizens in developed countries increasing, there is an increased need to provide medical care to the average citizen. As such, an aging population translates into increasing [...]
Our research into the products, technologies, companies and markets for tissue engineering and cell therapy has revealed that the 2009 market was at $6.9 billion. The market has grown dramatically, in commercialized products and company activity, over the past few years and is on an accelerated growth rate as technology hurdles are overcome and clinical [...]
The number of competitors developing and marketing cell therapy and tissue engineering products is extraordinary. But since approved clinical applications are proliferating and the resulting market has been driving dramatic double-digit-plus growth, it's unsurprising that competitors from extreme sides of the medical technology industry — drug, device, and biotech — are converging on this lucrative [...]
The number of companies with approved products and measurable revenues in the field of cell therapy and tissue engineering has exceeded the expectation of many (though not all) in the industry. Markets such as cell/tissue are often characterized by overestimated evaluations of commercial potential and underestimated consideration of the actual challenges. Indeed many technology challenges [...]
Market drivers that vary geographically account for some big differences in the distribution of the coronary stent market across the currently available stent types, and these differences will continue when bioabsorbable stents (and others) are introduced to the market over the next few years. The local market forces dictating these differences include: Regulatory timelines in [...]
One of the key areas of interest for development of products in surgical sealing, closure and hemostasis is in neural tissue surgery, encompassing chronic stroke, spinal cord trauma, neurovascular defects, and brain tumor treatments. In the U.S. alone, there were some 5.6 million patients in this category in 2008 who could benefit from these products. [...]
Contact:
